Clinical features and effect of antiviral therapy on anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis C

Journal of Hepatology

Volumn 50, Issue 6, 2009, Pages 1093-1101

  Ferri, Silvia ^a   Muratori, Luigi ^a   Quarneti, Chiara ^a   Muratori, Paolo ^a   Menichella, Rita ^a   Pappas, Georgios ^a   Granito, Alessandro ^a   Ballardini, Giorgio ^b   Bianchi, Francesco B ^a   Lenzi, Marco ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Rimini Hospital   (Italy)

Author keywords

Anti Liver Kidney Microsome antibody (anti LKM1); Hepatic immunohistochemistry; Hepatitis C virus; Hepatitis flare; Interferon treatment

Indexed keywords

ANTIBODY; CORTICOSTEROID; IMMUNOGLOBULIN G; INTERFERON; LIVER KIDNEY MICROSOMAL ANTIBODY TYPE 1; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; UNCLASSIFIED DRUG;

ADULT; ANTIVIRAL THERAPY; ARTICLE; AUTOIMMUNITY; CD8+ T LYMPHOCYTE; CELL COUNT; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; IMMUNE SYSTEM; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; AUTOANTIBODIES; AUTOIMMUNITY; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOGLOBULIN G; INTERFERONS; KIDNEY; LIVER; MALE; MICROSOMES; MIDDLE AGED; RIBAVIRIN; YOUNG ADULT;

EID: 67349138708     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.02.020     Document Type: Article

References (44)

1. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 36 Suppl (2002) S21-S29
2. Cacoub P., Poynard T., Ghillani P., Charlotte F., Olivi M., Piette J.C., et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 42 (1999) 2204-2212
3. Nieters A., Kallinowski B., Brennan P., Ott M., Maynadie M., Benavente Y., et al. Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH. Gastroenterology 131 (2006) 1879-1886
4. Lenzi M., Bellentani S., Saccoccio G., Muratori P., Masutti F., Muratori L., et al. Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort. Gut 45 (1999) 435-441
5. Muratori P., Muratori L., Stroffolini T., Pappas G., Terlizzi P., Ferrari R., et al. Prevalence of non-organ specific autoantibodies in HCV-infected subjects in the general population. Clin Exp Immunol 131 (2003) 118-121
6. Cassani F., Cataleta M., Valentini P., Muratori P., Giostra F., Francesconi R., et al. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology 26 (1997) 561-566
7. Nishioka M., Morshed S.A., Kono M., Himoto T., Parveen S., Arima K., et al. Frequency and significance of antibodies to P450IID6 protein in Japanese patients with chronic hepatitis C. J Hepatol 26 (1997) 992-1000
8. Yee L.J., Kelleher P., Goldin R.D., Marshall S., Thomas H.C., Alberti A., et al. Antinuclear antibodies (ANA) in chronic hepatitis C virus infection: correlates of positivity and clinical relevance. J Viral Hepat 11 (2004) 459-464
9. Pileri P., Uematsu Y., Campagnoli S., Galli G., Falugi F., Petracca R., et al. Binding of hepatitis C virus to CD81. Science 282 (1998) 938-941
10. Muratori L., Gibellini D., Lenzi M., Cataleta M., Muratori P., Morelli M.C., et al. Quantification of hepatitis C virus-infected peripheral blood mononuclear cells by in situ reverse transcriptase-polymerase chain reaction. Blood 88 (1996) 2768-2774
11. Pal S., Sullivan D.G., Kim S., Lai K.K., Kae J., Cotler S.J., et al. Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: implications of HCV lymphotropism. Gastroenterology 130 (2006) 1107-1116
12. Bogdanos D.P., Lenzi M., Okamoto M., Rigopoulou E.I., Muratori P., Ma Y., et al. Multiple viral/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus infected patients is associated with the possession of HLA B51. Int J Immunopathol Pharmacol 17 (2004) 83-92
13. Yamamoto A.M., Cresteil D., Boniface O., Clerc F.F., and Alvarez F. Identification and analysis of cytochrome P459IID6 antigenic sites recognized by anti-liver-kidney microsome type-1 antibodies (LKM 1). Eur J Immunol 23 (1993) 1105-1111
14. Kerkar N., Choudhuri K., Ma Y., Mahmoud A., Bogdanos D.P., Muratori L., et al. Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol 170 (2003) 1481-1489
15. Muratori L., Lenzi M., Ma Y., Cataleta M., Mieli-Vergani G., Vergani D., et al. Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease. Gut 37 (1995) 406-412
16. Marceau G., Lapierre P., Béland K., Soudeyns H., and Alvarez F. LKM1 autoantibodies in chronic hepatitis C infection: a case of molecular mimicry?. Hepatology 42 (2005) 675-682
17. Muratori P., Czaja A.J., Muratori L., Granito A., Guidi M., Ferri S., et al. Evidence of a genetic basis for the different geographic occurrences of liver/kidney microsomal antibody type 1 in hepatitis C. Dig Dis Sci 52 (2007) 179-184
18. Jurado A., Cardaba B., Jara P., Cuadrado P., Hierro L., de Andrés B., et al. Autoimmune hepatitic type 2 and hepatitic C virus infection: study of HLA antigens. J Hepatol 26 (1997) 983-991
19. Muratori L., Parola M., Ripalti A., Robino G., Muratori P., Bellomo G., et al. Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane. Gut 46 (2000) 553-561
20. Muratori P., Muratori L., Guidi M., Granito A., Susca M., Lenzi M., et al. Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C. Clin Infect Dis 40 (2005) 501-507
21. Muratori L., Zauli D., Giostra F., Ballardini G., Lenzi M., Cassani F., et al. LKM1 appearance in a HLA-DR3+ patient with chronic hepatitis C during interferon treatment. J Hepatol 18 (1993) 259-260
22. Muratori L., Lenzi M., Cataleta M., Giostra F., Cassani F., Ballardini G., et al. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C. J Hepatol 21 (1994) 199-203
23. Todros L., Saracco G., Durazzo M., Abate M.L., Touscoz G., Scaglione L., et al. Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes. Hepatology 22 (1995) 1374-1378
24. Garci{dotless}́a-Buey L., Garci{dotless}́a-Monzón C., Rodriguez S., Borque M.J., Garci{dotless}́a-Sánchez A., Iglesias R., et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 108 (1995) 1770-1777
25. Dalekos G.N., Wedemeyer H., Obermayer-Straub P., Kayser A., Barut A., Frank H., et al. Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment. J Hepatol 30 (1999) 366-375
26. Guadagnino V., Stroffolini T., Rapicetta M., Costantino A., Kondili L.A., Menniti-Ippolito F., et al. Prevalence, risk factors and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology 26 (1997) 1006-1011
27. Alvarez F., Berg P.A., Bianchi F.B., Bianchi L., Burroughs A.K., Cancado E.L., et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31 (1999) 929-938
28. NIH consensus statement on management of hepatitis C, 2002. NIH Consens State Sci Statements 2002;19:1-46.
29. Muratori L., Cataleta M., Muratori P., Lenzi M., and Bianchi F.B. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut 42 (1998) 721-726
30. Zauli D., Ghetti S., Grassi A., Descovich C., Cassani F., Ballardini G., et al. Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. Hepatology 25 (1997) 1105-1107
31. Batts K.P., and Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 19 (1995) 1409-1417
32. Ballardini G., De Raffele E., Groff P., Bioulac-Sage P., Grassi A., Ghetti S., et al. Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus-reinfected liver. Liver Transpl 8 (2002) 10-20
33. Krawczynsky K., Beach M.J., Bradley D.W., Kuo G., Di Bisceglie A.M., Houghton M., et al. Hepatitis C virus antigen in hepatocytes: immunomorphological detection and identification. Gastroenterology 103 (1992) 622-629
34. Ballardini G., Groff P., Pontisso P., Giostra F., Francesconi R., Lenzi M., et al. Hepatitis C virus genotype, tissue HCV antigens, hepatocellular expression of HLA-A, B, C and intercellular adhesion-1 molecules. Clues to pathogenesis of hepatocellular damage and response to interferon treatment in patients with chronic hepatitis C. J Clin Invest 95 (1995) 2067-2075
35. Mackay I.R., Leskovsek N.V., and Rose N.R. Cell damage and autoimmunity: a critical appraisal. J Autoimmun 30 (2008) 5-11
36. Gatselis N.K., Georgiadou S.P., Tassopoulos N., Zachou K., Liaskos C., Hatzakis A., et al. Impact of parietal cell autoantibodies and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis C virus infection: a pilot study. World J Gastroenterol 11 (2005) 482-487
37. Iijima Y., Kato T., Miyakawa H., Ogino M., Mizuno M., Sugihara K., et al. Effect of interferon therapy on Japanese chronic hepatitis C virus patients with anti-liver/kidney microsome autoantibody type 1. J Gastroenterol Hepatol 16 (2001) 782-788
38. Duclos-Vallée J.C., Nishioka M., Hosomi N., Arima K., Leclercq A., Bach J.F., et al. Interferon therapy in LKM-1 positive patients with chronic hepatitis C: follow up by a quantitative radioligand assay for CYP2D6 antibody detection. J Hepatol 28 (1998) 965-970
39. Saracco S., Sostegni R., Ghisetti V., Rocca G., Cariti G., Andreoni M., et al. Hepatitis C virus genotypes in a non-cirrhotic Italian population with chronic hepatitis C: correlation with clinical, virological and histological parameters. Results of a prospective multicentre study. J Viral Hepat 7 (2000) 124-129
40. Monti V., Aghemo A., Rumi M.G., Donato M.F., Del Ninno E., and Colombo M. The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies. Antivir Ther 10 (2005) 715-720
41. Kogure T., Ueno Y., Fukushima K., Nagasaki F., Inoue J., Kakazu E., et al. Fulminant hepatic failure in a case of autoimmune hepatitis in hepatitis C during peg-interferon-alpha 2b plus ribavirin treatment. World J Gastroenterol 13 (2007) 4394-4397
42. Coriat R., and Podevin P. Fulminant autoimmune hepatitis after successful interferon treatment in an HIV-HCV co-infected patient. Int J STD AIDS 19 (2008) 208-210
43. Zeuzem S., Welsch C., and Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis 23 Suppl (2003) 23-28
44. Alexander W.S., and Hilton D.J. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune system. Annu Rev Immunol 22 (2004) 503-529